Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Neurological Biomarkers Market Outlook (2023 to 2033)

The global neurological biomarkers market is estimated to reach a valuation of US$ 8 billion in 2023. As per Future Market Insights (FMI) analysis, the neurological biomarkers market size is expected to surpass US$ 12.5 billion in the next decade. Between 2023 and 2033, the market has been forecast to register a 4.6% CAGR.

In their healthcare business, key players have a central platform for storing, managing, and analyzing biomarker and multi-omics data. The Human Genome Project's emergence provided researchers with new molecular tools for gene identification and gene expression. It allowed researchers to detect genetic flaws linked to complicated disorders, including common neurological ailments, ushering in a new era of study.

Customized antibodies and assays are developed by key players to measure unique clinical biomarkers in a wide range of neurodegenerative disorders and conditions, including Alzheimer's disease, Parkinson's disease, and traumatic brain injury. Their tests allow for early identification of symptoms before they arise, delivering vital information from the medication research phase to clinical practice, therefore improving the lives of patients. This development is expected to boost the market further.

For instance, the 'TaqMan Gene Expression Assays enable researchers to employ real-time PCR to analyze how gene expression changes in samples collected from a person suffering from a complicated ailment. Furthermore, TaqMan Assays can be used in in-vitro investigations that focus on a specific genetic or environmental component that is hypothesized to be implicated in complex disease.

Cerebrospinal Fluid (CSF) biomarkers and neurofilament proteins, according to experts, should be stable during long-term preservation. However, there are few studies and some evidence that freezing and thawing might cause structural alterations in CSF samples. Increasing CSF sample storage might result in experimental data that can be used to solve this topic. Such studies provide opportunities for market players and act as propellers for the market.

All of the research conducted by significant firms is evidence-based, and patients are managed using a test based on facts rather than subjective interpretation. Furthermore, they strive for safe therapies by limiting needless CT scan radiation exposure. Most key players have extensive experience in executing and cooperating on clinical research. They feel that collaboration is critical in developing novel biomarkers and therapies for the brain. Hence, key players engage in collaborative work and aid the market.

Moreover, they also allow their customers to collaborate by contacting them to handle brain damage and neurological illnesses. In addition, they provide access to a constantly expanding library of thousands of highly-curated disease-relevant experiments, including immunological, neurological, metabolic, and cardiovascular illnesses, with a special focus on expression studies, to speed predictive biomarkers and therapeutic target development, thus helping market growth.

Attributes Details
Neurological Biomarkers Market HCAGR (2017 to 2022) 5.2%
Neurological Biomarkers Market CAGR (2023 to 2033) 4.6%
Market Size for Neurological Biomarkers (2023) US$ 8 billion
Market Size for Neurological Biomarkers (2033) US$ 12.5 billion
Market Size for Neurological Biomarkers - Absolute Dollar Growth US$ 4.6 billion

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

A Contrast with the Historical Market Scenario

The statistics accumulated by Future Market Insights reveal the global forum of neurological biomarkers, which has witnessed an unprecedented surge over the past few years. The key providers in the market are in conjunction with the increasing demand for neurological biomarkers. There has been a gradual rise from a CAGR of 5.2% registered during the period of 2017 to 2022 and is likely to decrease at an adequate 4.6% in the forecast period.

Complications in the basic understanding of the molecular signatures of biological processes, as well as the neglect of treatment of neurological disorders, may slightly decline the market growth during the forecast period. On the contrary, spreading awareness regarding the benefits of predictive biomarkers may create several market opportunities for key clinicians.

Comparative Analysis of Adjacent Markets

Neurological Biomarkers Market:

Attributes Neurological Biomarkers Market
CAGR (2023 to 2033) 4.6%
Market Value (2033) US$ 12.5 billion
Growth Factor The increased use of neurological biomarkers to indicate normal biological and pathogenic mechanisms in response to a therapeutic approach.
Opportunity Increased customized medicine and the development of novel neurological biomarkers.
Restraints The lack of pre-analytical testing, as well as legal concerns associated with the early detection of Alzheimer's and Parkinson's illnesses

Rare Neurological Disease Treatment Market:

Attributes Rare Neurological Disease Treatment Market
CAGR (2023 to 2033) 8.4%
Market Value (2033) US$ 20.11 billion
Growth Factor Increasing R&D methods for treating neurological ailments, as well as developing government regulations throughout the world to raise awareness for these diseases, may boost the market.
Opportunity Rapid advancements in healthcare and substantial socioeconomic changes result in altered lifestyles.
Restraints The absence of conventional treatment to cure these ailments has been a major impediment to the growth of the global neurological disease treatment market.

Neurology Clinical Trials Market:

Attributes Neurology Clinical Trials Market
CAGR (2023 to 2033) 6.3%
Market Value (2033) US$ 11.16 billion
Growth Factor Pharma and medical device businesses have partnered together to provide better knowledge and treatment which may drive market growth during the forecast period.
Opportunity Virtual clinical trials, remote monitoring, and wearable gadgets may help to achieve the objective of making clinical trials more patient-centered.
Restraints Due to the high expense and the high failure rates of clinical trials across therapeutic areas, numerous pharmaceutical companies are fleeing the market.
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Category-wise Insights

Alzheimer's Disease - By Application Type

By application type, the market is segmented into Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, depression, multiple sclerosis, and spinal muscular atrophy. It has been studied by the analysts at Future Market Insights that the Alzheimer's disease segment is estimated to hold a major market share of 5.2% through the forecast period.

The vital elements determining the momentum of this segment are:

  • The increasing disease burden and the availability of clinically useful goods, such as imaging biomarkers-amyloid PET tracers for diagnosis, are attributed to the growth of the segment.
  • The government and non-profit organizations are offering several research possibilities that might boost segment growth.

Pharma & Biotech Companies - By End User Type

By end-user type, the market is segmented into research organizations, pharma & biotech companies, and clinical diagnostics. It has been studied by the analysts at Future Market Insights that the pharma & biotech companies segment is estimated to hold the largest market share through the forecast period.

  • The pivotal aspects determining the momentum of this segment are:
  • The growth of this segment is owing to the rising use of biomarkers in medication discovery and development by pharmaceutical firms and ambulatory surgery centers (ASCs).
  • Key clinicians are involved in different Research and Development (R&D) activities in the field of biomarkers that contribute to the considerable share of this segment.

Crucial Position of Neuropathologists & Other Drivers

Recent biomarker breakthroughs, such as biomarker signatures, are making neurological illnesses more curable. As a result, non-invasive diagnostics, faster medication development, and earlier diagnosis are now possible. In addition, key players are conducting clinical trials and biomarker research and development (R&D) to provide more precise findings for neurological illnesses, which is likely to increase demand for neurological biomarkers throughout the projected period.

The need for verifying and finding biomarkers in big populations is enormous. This strategy is being used in the research process, which increases the likelihood of the neurological biomarkers market growing rapidly in the next years. Furthermore, neuropathologists are expected to determine the nomination and delineation of suitable treatment regimens as new and fresh neuroscience biomarkers are introduced.

Precision medicine, also known as customized medicine, has been identified as one of the most promising techniques for treating a variety of disorders. The increasing frequency of the brain and other nervous system tumors is one of the primary reasons driving the market growth. It is becoming more used as a diagnostic technique, assisting in the identification of certain biological markers.

Region-wise Analysis

Country United States
CAGR (2023 to 2033) 3.9%
HCAGR (2017 to 2022) 4.3%
Country United Kingdom
CAGR (2023 to 2033) 3.5%
HCAGR (2017 to 2022) 4.3%
Country China
CAGR (2023 to 2033) 5.9%
HCAGR (2017 to 2022) 6.3%
Country Japan
CAGR (2023 to 2033) 5.3%
HCAGR (2017 to 2022) 6%
Country India
CAGR (2023 to 2033) 6.1%
HCAGR (2017 to 2022) 7.3%

Presence of Well-known Neurological Specialists in the USA Involved in Extensive Research

Attributes Details
USA Market Size (2033) US$ 3.9 billion
USA Market Absolute Dollar Growth (US$ million/billion) US$ 1.2 billion

North America is one of the leading neurological biomarkers markets. The USA is the most lucrative market in the region, with a revenue share of 3.9%. The value of the smart home devices market in the USA is estimated to reach a high of US$ 3.9 billion by the year 2033. The dominance of the country is attributed in part to its relatively high illness burden, adoption of biomarkers for diagnostic, therapeutic development, and prognostic reasons, and a boost in research funding.

The global cost of dementia was $818 billion in 2015, and it is anticipated to reach $2 Tn by 2030, according to the WHO. Key stakeholders in the United States are delivering an interactive teaching course that includes insights from world-renowned specialists on the clinical utility of standardized CSF testing to enable a fast diagnosis of Alzheimer's disease.

To speed clinical development projects, top scientists and industry-leading laboratories drive the creation of more advanced biomarker strategies, as well as specialized tests and on-target protocol assistance. Furthermore, prominent doctors claim to have extensive neurodegeneration biomarker experience to assist in making decisions. They have a strategic focus on neurodegeneration, neuroinflammation, traumatic brain injuries (TBI), and multiple sclerosis (M.S.), and they collaborate with a fast-developing network of university researchers, pharmaceutical, and biotech partners to enhance head health research.

In Germany, Key Clinicians are Using AI to Produce Predictive Biomarkers on Neural Network Activity!

Germany is a market with several market opportunities and a favorable revenue share. Key players in Germany provide research facilities that target all aspects of neurodegenerative illnesses (such as Alzheimer's, Parkinson's, and Amyotrophic lateral sclerosis) in order to create innovative preventive, treatment, and healthcare techniques. On a national and global scale, they work closely with universities, university hospitals, and other research institutes.

Key players strive to produce so-called functional biomarkers based on neural network activity utilizing artificial intelligence and unique mathematical techniques. These biomarkers are supposed to disclose whether the network is functioning properly or not, as well as if a certain medicine changes this state, which ultimately assists in the identification of potential drugs. Moreover, driven by a passion for promoting human health for all, they are establishing a network of discovery, connecting scientists, and exchanging thoughts, ideas, and knowledge in order to advance neuroscience research.

Japan: A Country with A Higher Geriatric Population, Possibly Suffering from Neurological Ailments

Attributes Details
Japan Market Size (2033) US$ 643.8 million
Japan Market Absolute Dollar Growth (US$ million/billion) US$ 259.5 million

The Asia Pacific currently holds a notable share of the neurological biomarkers market, with Japan and India as its most lucrative markets. This is attributed to a growing number of clinical studies being done in developing nations such as India and China, as well as rising illness rates and growing demand for targeted therapies in the central nervous system, which are projected to fuel the biomarkers market.

Japan holds a revenue share of 5.3%, with an approximated valuation of US$ 643.8 million by 2033. The country has a strong position in the neuroimaging market, owing to the launch of unique solutions such as PET scanners with motion correction and the development of new IVD tests, which are expected to catalyze the growth of the medical device industry in the country.

Japan is a country with a high number of elderly people. As the geriatric population grows, it is expected that the number of patients suffering from neurodegenerative disorders may grow as well. As the chance of getting various diseases grows with age, numerous biomarkers that could be used to evaluate diseases are being developed. These biomarkers can detect the presence of diseases as well as track their progression and treatment success.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Key Players in India are Bringing Breakthrough Discoveries in Neurological Disorders

Attributes Details
India Market Size (2033) US$ 354 million
India Market Absolute Dollar Growth (US$ million/billion) US$ 157.9 million

India is currently the largest neurological biomarkers market and holds a high revenue share of 6.1%, with an approximated valuation of US$ 354 million by 2033. In India, key players strive to alter the future of healthcare by using ultrasensitive biomarker detection. A certain market player has a team of empowered researchers that use their ‘Simoa’ precision tools, diverse menu of assay kits, and bespoke assay creation services to bring breakthrough discoveries in illness and therapy to the forefront.

The digital health solutions offered by regional players enable the development of methodologies that provide illness diagnosis far earlier, improved prognoses, and enhanced treatment ways to improve the population's quality of life and lifespan for future generations.

Newcomers are Catching Up with Key Players with Innovative Strategies: Start-up Sphere

Start-up companies are offering additional therapeutic solutions, as well as advanced technology to provide ample biomarkers in neurological disorders:

  • SpinTech - It creates software for brain imaging. The firm provides MRI processing software that reduces the time required for full brain image capture. It also aids in the visualization, measurement, and identification of neurological biomarkers. Furthermore, it focuses on the diagnosis and treatment of TBI, dementia, stroke, and Parkinson's disease. SPIN-SWI, their flagship platform, provides 3D gradient-echo brain imaging, and SPIN-STAGE, their other platform, provides multi-contrast gradient-echo images.
  • Altoida - It offers an AI-powered tool for forecasting the development of Alzheimer's disease. The business has created activities that provide neuromotor biomarkers, which they believe may be used to diagnose Alzheimer's disease.
  • Valted Seq - It creates therapeutic treatments and biomarkers for the treatment of neurodegenerative illnesses. Using single-cell sequencing data, the business is developing precision treatments and new biomarkers for a variety of neurological illnesses, including Alzheimer's and Parkinson's.

Key Companies Transforming the Neurological Biomarkers Market Space

The presence of a considerable number of key companies in several regions is contributing to market growth. Ongoing research and development (R&D) activities to develop advanced technologies, as well as new product innovation, further creates numerous opportunities for the neurological biomarkers market share.

Recent Developments:

  • In August 2020, Johnson & Johnson Services, Inc. has entered into a collaboration agreement with Enigma Biomedical Group to evaluate new neuroimaging biomarkers-JNJ-64413739 and JNJ-64511070-to better understand Alzheimer's disease and other dementias.
  • In November 2021, Eisai Co. Ltd. and Biogen Inc. presented data on the use of plasma-based biomarkers in Phase 3 AHEAD 3-45 trial of lecanemab (BAN2401), an experimental anti-amyloid beta (A) protofibril antibody for Alzheimer's disease.
  • In October 2021, Diadem announced the release of clinical data demonstrating that their AlzoSure biomarker test may forecast the course of Alzheimer's disease years before symptoms appear.
  • In September 2020, Novartis Pharma AG and Siemens Healthineers inked a master cooperation agreement to invent, develop, and sell diagnostic tests for Novartis' pharmaceutical portfolio. The first program promotes the development of a serum NFL immunoassay to complement Novartis' MS and other neuroscience operations.

TOP MARKET PLAYERS OF THE NEUROLOGICAL BIOMARKERS MARKET

  • Quanterix
  • Qiagen
  • ADx NeuroSciences NV
  • Merck KGaA
  • Enrolmmun
  • Thermo Fisher Scientific
  • ACOBIOM
  • Banyan Biomarkers Inc.
  • Olink Biosciences
  • Bio-Rad Laboratories Inc.

Key Segments Profiled in the Neurological Biomarkers Market Survey

By Type:

  • Genomics Biomarkers
  • Proteomics Biomarkers
  • Metabolomics Biomarkers
  • Imaging Biomarkers
  • Others

By Application:

  • Alzheimer's Disease
  • Parkinson's Disease
  • Huntington's Disease
  • Schizophrenia
  • Depression
  • Multiple Sclerosis
  • Spinal Muscular Atrophy

By End User:

  • Research Organizations
  • Pharma & Biotech Companies
  • Clinical Diagnostics

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • Middle East and Africa (MEA)
  • Europe

Frequently Asked Questions

How is the Neurological Biomarkers Market Growing?

The neurological biomarkers market is predicted to grow at a CAGR of 4.6% during the forecast period.

Why does the Neurological Biomarkers Market have adequate growth potential?

Growing use of neurological biomarkers to identify biological and pathological systems concerning treatment strategies.

Where is the Neurological Biomarkers Market most dominant?

India is expected to hold a major share of the market, followed by China.

Table of Content

1. Executive Summary | Neurological Biomarkers Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ million) Analysis, 2017 to 2022

    4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ million) Analysis By Type, 2017 to 2022

    5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Type, 2023 to 2033

        5.3.1. Genomics Biomarker

        5.3.2. Proteomics Biomarkers

        5.3.3. Metabolomics Biomarkers

        5.3.4. Imaging Biomarkers

        5.3.5. Others

    5.4. Y-o-Y Growth Trend Analysis By Type, 2017 to 2022

    5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033

6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ million) Analysis By Application, 2017 to 2022

    6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Application, 2023 to 2033

        6.3.1. Alzheimer's Disease

        6.3.2. Parkinson's Disease

        6.3.3. Huntington's Disease

        6.3.4. Schizophrenia

        6.3.5. Depression

        6.3.6. Multiple Sclerosis

        6.3.7. Spinal Muscular Atrophy

    6.4. Y-o-Y Growth Trend Analysis By Application, 2017 to 2022

    6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033

7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ million) Analysis By End User, 2017 to 2022

    7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By End User, 2023 to 2033

        7.3.1. Research Organizations, Pharma & Biotech Companies

        7.3.2. Clinical Diagnostics

    7.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2022

    7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ million) Analysis By Region, 2017 to 2022

    8.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. Middle East and Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022

    9.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. The USA

            9.2.1.2. Canada

        9.2.2. By Type

        9.2.3. By Application

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Type

        9.3.3. By Application

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022

    10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Argentina

            10.2.1.4. Rest of Latin America

        10.2.2. By Type

        10.2.3. By Application

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Type

        10.3.3. By Application

        10.3.4. By End User

    10.4. Key Takeaways

11. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022

    11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. France

            11.2.1.3. The United Kingdom

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Russia

            11.2.1.7. Rest of Europe

        11.2.2. By Type

        11.2.3. By Application

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Type

        11.3.3. By Application

        11.3.4. By End User

    11.4. Key Takeaways

12. Asia Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022

    12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. India

            12.2.1.3. Japan

            12.2.1.4. Australia & New Zealand

            12.2.1.5. ASEAN

            12.2.1.6. Rest of Asia Pacific

        12.2.2. By Type

        12.2.3. By Application

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Type

        12.3.3. By Application

        12.3.4. By End User

    12.4. Key Takeaways

13. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022

    13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Rest of MEA

        13.2.2. By Type

        13.2.3. By Application

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Type

        13.3.3. By Application

        13.3.4. By End User

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. The USA

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Type

            14.1.2.2. By Application

            14.1.2.3. By End User

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Type

            14.2.2.2. By Application

            14.2.2.3. By End User

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Type

            14.3.2.2. By Application

            14.3.2.3. By End User

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Type

            14.4.2.2. By Application

            14.4.2.3. By End User

    14.5. Argentina

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Type

            14.5.2.2. By Application

            14.5.2.3. By End User

    14.6. Germany

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Type

            14.6.2.2. By Application

            14.6.2.3. By End User

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Type

            14.7.2.2. By Application

            14.7.2.3. By End User

    14.8. The United Kingdom

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Type

            14.8.2.2. By Application

            14.8.2.3. By End User

    14.9. Spain

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Type

            14.9.2.2. By Application

            14.9.2.3. By End User

    14.10. Italy

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Type

            14.10.2.2. By Application

            14.10.2.3. By End User

    14.11. Russia

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Type

            14.11.2.2. By Application

            14.11.2.3. By End User

    14.12. China

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Type

            14.12.2.2. By Application

            14.12.2.3. By End User

    14.13. India

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Type

            14.13.2.2. By Application

            14.13.2.3. By End User

    14.14. Japan

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Type

            14.14.2.2. By Application

            14.14.2.3. By End User

    14.15. Australia & New Zealand

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Type

            14.15.2.2. By Application

            14.15.2.3. By End User

    14.16. ASEAN

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Type

            14.16.2.2. By Application

            14.16.2.3. By End User

    14.17. GCC Countries

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Type

            14.17.2.2. By Application

            14.17.2.3. By End User

    14.18. South Africa

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Type

            14.18.2.2. By Application

            14.18.2.3. By End User

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Type

        15.3.3. By Application

        15.3.4. By End User

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Quanterix

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Qiagen

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. ADx NeuroSciences NV

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Merck KGaA

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Enrolmmun

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Thermo Fisher Scientific

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. ACOBIOM

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Banyan Biomarkers, Inc.

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Olink Biosciences

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Bio-Rad Laboratories Inc.

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Recommendations

Healthcare

Neurology Digital Therapeutics Market

Published : December 2021

Explore Healthcare Insights

View Reports

Neurological Biomarkers Market